Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Cabaletta Bio is a clinical-stage biotechnology company developing engineered T cell therapies targeting autoimmune diseases. Its proprietary CABA platform includes CARTA and CAART strategies to reset or eliminate disease-causing B cells. The company’s lead candidate, rese-cel, aims to provide durable, potentially curative responses across multiple autoimmune conditions. It collaborates with academic and manufacturing partners to advance innovative, scalable therapies with a focus on safety and broad patient impact.
This description was generated via AI from an annual report. Updated about 1 year ago.